Our News
Alnylam Publishes 2021 Patient Access Philosophy Report
December 21, 2021
Alnylam Pharmaceuticals
As part of our ongoing efforts to ensure that our innovative therapies can be accessed by patients who may benefit them, which is guided by Alnylam's Patient Access Philosophy, and commitment to transparency, we're proud to publish Alnylam's 2021 Patient Access Philosophy report.
The 2021 report summarizes Alnylam’s latest collaborations with payer, provider, regulatory, distributor, and advocacy partners. Importantly, the report demonstrates Alnylam’s steadfast commitment to innovative access initiatives as the company serves more patients and enters new geographies, which is instrumental to its P5x25 strategic plan focused on patients, products, pipeline, performance, and profitability. This year’s report also highlights how Alnylam has supported patient access to RNAi therapeutics amidst the ongoing global pandemic.
Our team has always understood that the science of RNAi therapeutics was step one. The ultimate challenge would be ensuring our patients globally have access to our therapies, independent of their financial status and external events. I very proud of the progress we've made, reflected in this report, and believe that we're transforming the way patient access is conceived and approached globally. – John Maraganore, PhD, Alnylam CEO
Highlights of the 2021 Patient Access Philosophy Report include:
Supporting patients from clinical development of new therapies through commercialization: Around the world, more than 2,250 commercial patients managing rare diseases now rely on Alnylam’s therapies. Alnylam’s global programs and partnerships inform and empower patients to get access to education and care, guided by the belief that no patient should have to wait for hope. Through these partnerships, Alnylam has:
- Provided access to its therapies to many patients around the world via the establishment of compassionate use and early access programs.
- Helped to provide greater access to home administration for all three of its approved therapies.
- Ensured the majority of commercially insured U.S. patients enrolled in Alnylam’s patient services program faced little or no out-of-pocket costs.
- Provided training for more than 50 patient advocates from 18 European countries across its therapeutic areas.
- Supported independent genetic testing programs that reached nearly 59,000 people in the U.S., Canada, Brazil, and Europe.
Collaborating with more partners worldwide to define value and support access: Alnylam’s growth in new markets is accompanied by extensive collaboration around value-based care and responsible pricing. By working with local governments, private and public payers, and distribution partners, Alnylam continues to produce innovative solutions that remove barriers to care, globally. Through these partnerships, Alnylam has:
- Expanded its global footprint to more than 45 markets worldwide.
- Instituted zero arbitrary price increases worldwide.
- Realized 98% coverage for ONPATTRO® (patisiran), 94% for GIVLAARI® (givosiran), and 88% for OXLUMO® (lumasiran) across U.S. commercial and government insurers, including Medicare and Medicaid.
- For patients enrolled in Alnylam’s patient support program, 73% of ONPATTRO patients, 84% of GIVLAARI patients, and 92% of OXLUMO patients have zero cost sharing (no out-of-pocket payments) for the medicine.
- Established 14 new value-based agreements, achieving 43 total VBAs with U.S. payers (ONPATTRO - 19; GIVLAARI – 13; OXLUMO-11).
- Established availability of ONPATTRO, Alnylam’s first approved therapy, in more than 30 countries across Canada, Europe, Middle East and Africa (CEMEA) through direct reimbursement or expanded access.
- Achieved pricing and reimbursement for both ONPATTRO and GIVLAARI in Europe’s five largest markets (France, Germany, Italy, Spain, United Kingdom) within 20 months of the European Commission approval, faster than the average time to market for orphan drugs.
- Increased the number of Asia-Pacific countries where patients have access to Alnylam medicines to three.
We hope that you will take the time to read the 2021 Patient Access Philosophy Report and learn how we are doing our part to improve access worldwide.
